Insider Selling: FibroGen, Inc. (NASDAQ:FGEN) EVP Sells $34,795.68 in Stock

Posted by Defense World Staff on Jun 12th, 2023

FibroGen, Inc. (NASDAQ:FGEN – Get Rating) EVP Mark Eisner sold 2,042 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $17.04, for a total transaction of $34,795.68. Following the transaction, the executive vice president now directly owns 162,862 shares in the company, valued at approximately $2,775,168.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Eisner also recently made the following trade(s):

On Friday, June 2nd, Mark Eisner sold 1,090 shares of FibroGen stock. The stock was sold at an average price of $18.83, for a total value of $20,524.70.
On Tuesday, April 4th, Mark Eisner sold 9,182 shares of FibroGen stock. The stock was sold at an average price of $18.78, for a total transaction of $172,437.96.

FibroGen Stock Performance

Shares of FibroGen stock traded up $0.33 during trading on Monday, reaching $17.31. The company had a trading volume of 611,874 shares, compared to its average volume of 949,678. The firm’s fifty day moving average is $17.95 and its 200-day moving average is $18.85. FibroGen, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $25.69.

FibroGen (NASDAQ:FGEN – Get Rating) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). FibroGen had a negative net margin of 264.63% and a negative return on equity of 879.75%. The company had revenue of $36.16 million during the quarter, compared to analyst estimates of $31.52 million. During the same quarter last year, the company posted ($0.68) EPS. The business’s revenue for the quarter was down 40.6% compared to the same quarter last year. Equities analysts forecast that FibroGen, Inc. will post -2.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Institutional investors have recently made changes to their positions in the company. Altshuler Shaham Ltd bought a new stake in shares of FibroGen in the 4th quarter valued at approximately $28,000. Royal Bank of Canada boosted its holdings in shares of FibroGen by 45.3% in the 3rd quarter. Royal Bank of Canada now owns 2,314 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 721 shares during the period. Quantbot Technologies LP acquired a new position in shares of FibroGen in the 2nd quarter valued at about $39,000. Dark Forest Capital Management LP acquired a new position in shares of FibroGen in the 1st quarter valued at about $47,000. Finally, U.S. Capital Wealth Advisors LLC acquired a new position in shares of FibroGen in the 4th quarter valued at about $54,000. 76.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Cowen boosted their price objective on shares of FibroGen from $15.00 to $25.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 28th. The Goldman Sachs Group boosted their price objective on FibroGen from $9.00 to $16.00 and gave the stock a “sell” rating in a research note on Tuesday, February 21st. Stifel Nicolaus upgraded shares of FibroGen from a “hold” rating to a “buy” rating and lifted their price objective for the company from $23.00 to $32.00 in a research note on Thursday, June 1st. Finally, StockNews.com began coverage on shares of FibroGen in a research note on Thursday, May 18th. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.83.

FibroGen Company Profile

(Get Rating)

FibroGen, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer.